About Ileal sodium/bile acid cotransporter
Ileal sodium/bile acid cotransporter (SLC10A2) is a protein
from Homo sapiens identified by UniProt accession
Q12908, 348 residues long.
MolForge cross-references it against 0 known binders and
168 disease associations.
Target properties
| Protein name | Ileal sodium/bile acid cotransporter |
| UniProt accession | Q12908 |
| Gene | SLC10A2 |
| Organism | Homo sapiens |
| Length | 348 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (168)
Diseases linked to this target (Open Targets).
- bile acid malabsorption, primary, 1 · score 0.63
- primary ovarian insufficiency · score 0.63
- Alagille syndrome · score 0.56
- Pruritus · score 0.54
- Chronic constipation · score 0.51
- cholelithiasis · score 0.47
- familial intrahepatic cholestasis · score 0.46
- gallstones · score 0.39
- progressive familial intrahepatic cholestasis · score 0.39
- Constipation · score 0.38
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q12908-F1 | alphafold | PREDICTED | 82.69 | — |
Amino-acid sequence (348 residues)
MNDPNSCVDN ATVCSGASCV VPESNFNNIL SVVLSTVLTI LLALVMFSMG CNVEIKKFLG HIKRPWGICV GFLCQFGIMP LTGFILSVAF DILPLQAVVV LIIGCCPGGT ASNILAYWVD GDMDLSVSMT TCSTLLALGM MPLCLLIYTK MWVDSGSIVI PYDNIGTSLV SLVVPVSIGM FVNHKWPQKA KIILKIGSIA GAILIVLIAV VGGILYQSAW IIAPKLWIIG TIFPVAGYSL GFLLARIAGL PWYRCRTVAF ETGMQNTQLC STIVQLSFTP EELNVVFTFP LIYSIFQLAF AAIFLGFYVA YKKCHGKNKA EIPESKENGT EPESSFYKAN GGFQPDEK
Explore Ileal sodium/bile acid cotransporter with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets